Hypoxia imaging-directed radiation treatment planning

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue SUPPL. 13, 2006, Pages

  Rajendran, J G ^a,b   Hendrickson, K R G ^a   Spence, A M ^b   Muzi, M ^a   Krohn, K A ^a   Mankoff, D A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Image guided treatment; PET; Radiotherapy; Tissue hypoxia

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18; FLUOROTHYMIDINE F 18; GENE PRODUCT; RADIOISOTOPE; UNCLASSIFIED DRUG; GLUCOSE TRANSPORTER; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; RADIOPHARMACEUTICAL AGENT;

ARTICLE; ASTROCYTOMA; CANCER RADIOTHERAPY; CANCER RESISTANCE; COMPUTER ASSISTED RADIOTHERAPY; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; HYPOXIA; IMAGING SYSTEM; INTENSITY MODULATED RADIATION THERAPY; MICROENVIRONMENT; NEUTRON THERAPY; POSITRON EMISSION TOMOGRAPHY; RADIOSENSITIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING; CELL HYPOXIA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; NONHUMAN; RADIATION DOSE; REVIEW; TUMOR VOLUME; ANOXIA; HEAD AND NECK TUMOR; IMAGE PROCESSING; METHODOLOGY; NEOPLASM; PATHOPHYSIOLOGY; RADIOGRAPHY; RADIOTHERAPY; SCINTISCANNING;

ANOXIA; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY;

EID: 33746474625     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0135-1     Document Type: Article

References (94)

1. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:537-549
2. Kourkourakis MI, Giatromanolaki A, Sivridis E, Fezoulidis I. Cancer vascularization: implications in radiotherapy? Int J Radiat Oncol Biol Phys 2000;48:545s-553s
3. Scandurro AB, Weldon CW, Figueroa YG, Alam J, Beckman BS. Gene microarray analysis reveals a novel hypoxia signal transduction pathway in human hepatocellular carcinoma cells. Int J Oncol 2001;19:129-135
4. Villaret DB, Wang T, Dillon D, Xu J, Sivam D, Cheever MA, et al. Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 2000;110:374-381
5. Rajendran JG, Wilson D, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, et al. F-18 FMISO and F-18 FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nuc Med Mol Imaging 2003;30:695-704
6. Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999;59:4525-4528
7. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-468
8. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996;271:32253-32259
9. Guillemin K, Krasnow MA. The hypoxic response: huffing and HIFing. Cell 1997;89:9-12
10. Clavo AC, Wahl RL. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells. J Nucl Med 1996;37:502-506
11. Burgman P, Odonoghue JA, Humm JL, Ling CC. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 2001;42:170-175
12. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-2252
13. Hall EJ. Radiobiology for the radiologist. Lippincott Williams & Wilkins, Philadelphia, PA; 2000
14. Marples B, Greco O, Joiner MC, Scott SD. Molecular approaches to chemo-radiotherapy. Eur J Cancer 2002;38:231-239
15. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10-21
16. Fowler JF. Eighth annual Juan del Regato lecture. Chemical modifiers of radiosensitivity - theory and reality: a review. Int J Radiat Oncol Biol Phys 1985;11:665-674
17. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 2003;195:1-16
18. Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987;5:313-341
19. Rajendran JG, Meyer J, Schwartz DL, Kinahan PE, Cheng P, Hummel SM, et al. Imaging with F-18 FMISO-PET permits hypoxia directed radiotherapy dose escalation for head and neck cancer. J Nucl Med 2003;44:415, 127P
20. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171-1182
21. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000;6:157-162
22. Lee DJ, Moini M, Giuliano J, Westra WH. Hypoxic sensitizer and cytotoxin for head and neck cancer. Ann Acad Med Singapore 1996;25:397-404
23. Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:535-542
24. Rasey JS, Casciari JJ, Hofstrand PD, Muzi M, Graham MM, Chin LK. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat Res 2000;153:84-192
25. Prekeges JL, Rasey JS, Grunbaum Z, Krohn KH. Reduction of fluoromisonidazole, a new imaging agent for hypoxia. Biochem Pharmacol 1991;42:2387-2395
26. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229-237
27. Grierson JR, Link JM, Mathis CA, Rasey JS, Krohn KA. Radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med 1989;30:343-350
28. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-428
29. 18F] fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-2252
30. Liu RS, Chu LS, Yen SH, Chang CP, Chou KL, Wu LC, et al. Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole. Eur J Nucl Med 1996;23:1384-1387
31. 18F]fluoro-2-deoxy-D-glucose. Acta Oncol 2000;39:629-637
32. Yeh SH, Liu RS, Wu LC, Yang DJ, Yen SH, Chang CW, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996;23:1378-1383
33. Koch CJ, Evans SM. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv Exp Med Biol 2003;510:285-292
34. 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106-113
35. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155-1160
36. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of Cu-64-ATSM in vitro and in vivo in a hypoxic model. J Nucl Med 1999;40:177-183
37. Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med 2001;31:321-329
38. 4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005;61:1493-1502
39. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998;41:501-510
40. Zelefsky MJ, Leibel SA, Kutcher GJ, Fuks Z. Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol 1998;8:107-114
41. Dogan N, Leybovich LB, Sethi A, Emami B. Improvement of dose distributions in abutment regions of intensity modulated radiation therapy and electron fields. Med Phys 2002;29:38-44
42. Svensson H, Moller TR. Developments in radiotherapy. Acta Oncol 2003;42:430-442
43. Williams PC. IMRT: delivery techniques and quality assurance. Br J Radiol 2003;76:766-776
44. Webb S. The physical basis of IMRT and inverse planning. Br J Radiol 2003;76:678-689
45. Verhey LJ. Issues in optimization for planning of intensity-modulated radiation therapy. Semin Radiat Oncol 2002;12:210-218
46. Goffman TE, Glatstein E. Intensity-modulated radiation therapy. Radiat Res 2002;158:115-117
47. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 2001;51:880-914
48. Garden AS, Morrison WH, Rosenthal DI, Chao KS, Ang KK. Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Semin Radiat Oncol 2004;14:103-109
49. Eisbruch A, Foote RL, O'Sullivan B, Beitler JJ, Vikram B. Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets. Semin Radiat Oncol 2002;12:238-249
50. Alber M, Paulsen F, Eschmann SM, Machulla HJ. On biologically conformal boost dose optimization. Phys Med Biol 2003;48:N31-N35
51. Chao KS, Low DA, Perez CA, Purdy JA. Intensity-modulated radiation therapy in head and neck cancers: the Mallinckrodt experience. Int J Cancer 2000;90:92-103
52. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-560
53. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005;43:153-167
54. Rajendran JG, Schwartz DS, O'Sullivan J, Peterson LM, Ng P, Scarnhorst J, et al. Tumor hypoxia imaging with [F-18]FMISO PET in head and neck cancer: value of pre-therapy FMISO uptake in predicting survival. Clin Cancer Res; 2006; in press
55. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005;43:169-187
56. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-260
57. Schwartz DL, Ford EC, Rajendran J, Yueh B, Coltrera MD, Virgin J, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck 2005;27:478-487
58. Yap JT, Carney JP, Hall NC, Townsend DW. Image-guided cancer therapy using PET/CT. Cancer J 2004;10:221-233
59. Heron DE, Andrade RS, Flickinger J, Johnson J, Agarwala SS, Wu A, et al. Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report. Int J Radiat Oncol Biol Phys 2004;60:1419-1424
60. Esthappan J, Mutic S, Malyapa RS, Grigsby PW, Zoberi I, Dehdashti F, et al. Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 2004;58:1289-1297
61. 18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol 2005;50:2209-2224
62. 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 2005;5:152
63. Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol 2005;181:483-499
64. Mehta VK, Poen JC, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, et al. Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol 2001;24:155-159
65. Johnson CR, Schmidt-Ullrich RK, Wazer DE. Concomitant boost technique using accelerated superfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. Cancer 1992;69:2749-2754
66. Grills IS, Yan D, Martinez AA, Vicini FA, Wong JW, Kestin LL. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003;57:875-890
67. Ahmed RS, Kim RY, Duan J, Meleth S, De Los Santos JF, Fiveash JB. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys 2004;60:505-512
68. Allen N. Respiration and oxidative metabolism of brain tumors. In: Kirsch WM, Paoletti EG, Paoletti P, editors. The experimental biology of brain tumors. Springfield: Charles C. Thomas;, 1972. p 243-274
69. 15O and positron emission tomography: analytical techniques and preliminary results. Neuroradiology 1982;23:63-74
70. Lammertsma AA, Frackowiak RS. Positron emission tomography. Crit Rev Biomed Eng 1985;13:125-169
71. Rhodes CG, Wise RJ, Gibbs JM, Frackowiak RS, Hatazawa J, Palmer AJ, et al. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 1983;14:614-626
72. Tyler JL, Diksic M, Villemure JG, Evans AC, Meyer E, Yamamoto YL, et al. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 1987;28:1123-1133
73. Wise RJS, Thomas DGT, Lammertsma AA, Rhodes CG. PET scanning of human brain tumors. Prog Exp Tumor Res 1984;27:154-169
74. Baron JC, Rougemont D, Soussaline F, Bustany P, Crouzel C, Bousser MG, et al. Local interrelationships of cerebral oxygen consumption and glucose utilization in normal subjects and in ischemic stroke patients: a positron tomography study. J Cereb Blood Flow Metab 1984;4:140-149
75. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004;64:920-927
76. Evans SM, Judy KD, Dunphy I, Jenkins WT, Nelson PT, Collins R, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004;64:1886-1892
77. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Biol Phys 1994;29:427-431
78. 2O. J Nucl Med 2004;45:1851-1859
79. Liu Q. Constriction to hypoxia-reoxygenation in isolated mouse coronary arteries: role of endothelium and superoxide. J Appl Physiol 1999;87:1392-1396
80. 18F- fluorodeoxyglucose (FDG) positron emission tomography (PET). J Nucl Med 2001;42:abstract 250, 267P
81. Valk P, Mathis C, Prados M, Gilbert J, Budinger T. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133-2137
82. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983;52:997-1007
83. Lee SW, Fraass BA, Marsh LH, Herbort K, Gebarski SS, Martel MK, et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 1999;43:79-88
84. Nelson DF, Diener-West M, Horton J, Chang CH, Schoenfeld D, Nelson JS. Combined modality approach to treatment of malignant gliomas - re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988;6:279-284
85. Salazar OM, Rubin P, Feldstein ML, Pizzutiello R. High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys 1979;5:1733-1740
86. Davis LW. Malignant glioma - a nemesis which requires clinical and basic investigation in radiation oncology. Int J Radiat Oncol Biol Phys 1989;16:1355-1365
87. Green SB, Byar DP, Strike TA, Alexander E, Brooks WH, Burger PC, et al. Randomized comparisons of BCNU, streptozotocin, radiosensitizer, and fractionation of radiotherapy in the post-operative treatment of malignant glioma. Proc ASCO 1984;3:260
88. Nelson DF, Schoenfeld D, Weinstein AS, Nelson JS, Wasserman T, Goodman RL, et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study. Int J Radiat Oncol Biol Phys 1983;9:1143-1151
89. Griffin TW, Davis R, Laramore G, Hendrickson F, Rodrigues Antunez A, Hussey D, et al. Fast neutron radiation therapy for glioblastoma multiforme. Results of an RTOG study. Am J Clin Oncol 1983;6:661-667
90. Gross MW, Weber WA, Feldmann HJ, Bartenstein P, Schwaiger M, Molls M. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 1998;41:989-995
91. Douglas JG, Stelzer KJ, Mankoff DA, Tralins KS, Krohn KA, Muzi M, et al. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2006;64:886-891
92. Suzuki M, Nakamatsu K, Kanamori S, Okumra M, Uchiyama T, Akai F, Nishimura Y. Feasibility study of the simultaneous integrated boost (SIB) method for malignant gliomas using intensity-modulated radiotherapy (IMRT). Jpn J Clin Oncol 2003;33:271-277
93. Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D, et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 2004;45:1146-1154
94. 18F-fluorodeoxyglucose positron emission tomography targeting and simultaneous integrated boost for intensity-modulated radiosurgery and radiotherapy. J Neurosurg 2004;101(Suppl 3):381-389